Hepatic disease chronic hepatitis

CEA levels are elevated in benign diseases such as inflammatory bowel disease, chronic gastritis and peptic ulcer, cirrhosis, and hepatitis. CEA testing is recommended primarily to monitor patients after surgery for recurrent colorectal carcinoma. Twenty percent of colorectal carcinomas do not express CEA therefore, immunohistochemical methods are recommended to identify the negative cases. If a 5.0 ng/ml cutoff is used as the detection criterion, approximately 60 to 90 percent of the clinical cases will be detected for recurrences 2 to 10 months prior to clinical symptoms (37, 38). 

Suggested Alternatives for Differential Diagnosis Influenza, infectious mononucleosis, hepatitis, leptospirosis, infective endocarditis, malaria, tuberculosis, typhoid fever, cryptococcosis, histoplasmosis, ankylosing spondylitis and undifferentiated spondyloarthropathy, collagen vascular disease, chronic fatigue syndrome, malignancy, and osteomyelitis. 

Endocrine abnormalities Hypothyroidism Adrenal insufficiency Pituitary insufficiency Chronic renal disease Chronic inflammatory disease Granulomatous diseases Collagen vascular diseases Hepatic disease... 

In a report of human exposures, cited by lARC, vineyard workers exposed to HCBD (0.8-30mg/m ) and polychlorobutane (0.12-6.7mg/m ) showed multiple toxicological effects contributing to the development of hypotension, cardiac disease, chronic bronchitis, disturbances of nervous function, and hepatitis. ... 

It is indicated in renal transplantation, severe active rheumatoid arthritis unresponsive to other therapy, certain autoimmune diseases, chronic active hepatitis, idiopathic thrombocytopenic purpura and acquired haemolytic anaemia. 

There is epidemiologic evidence to suggest an increased prevalence of duodenal ulcers in patients with certain chronic diseases, but the pathophysiologic mechanisms of these associations are uncertain. A strong association exists in patients with systemic mastocytosis, multiple endocrine neoplasia type 1, chronic pulmonary diseases, chronic renal failure, kidney stones, hepatic cirrhosis, and ai-antitrypsin deficiency. An association may exist in patients with cystic fibrosis, chronic pancreatitis, Crohn s disease, coronary artery disease, polycythemia vera, and hyperparathyroidism. 

Gastrointestinal Diseases Chronic active hepatitis Crohn s disease Nontropical sprue Ulcerative colitis Neurologic Conditions Acute cerebral edema Multiple sclerosis Myasthenia gravis Eye Diseases Allergic conjunctivitis Exophthalmos Optic neuritis Scleritis Uveitis... 

GZ (23) is known to decrease elevated plasma levels of AST and ALT in various liver diseases. Thus it has been widely used for the treatment of chronic liver diseases (chronic viral hepatitis) in Japan for several years [82]. However, the mechanism of its transaminase-lowering action is not fully understood. Some studies suggested that the decrease of transaminase levels by GZ in patients with chronic viral hepatitis is mediated in part by inhibition of immune-mediated cytotoxicity against hepatocytes [83]. GZ (23) was shown to inhibit the cytotoxicity of CTL against antigen-presenting cells and also to suppress TNF-a induced cytotoxicity in the TNF-a sensitive cell line in vitro. A clinical study reported the use of GZ to bring about an improvement of hepatitis after liver transplantation performed for cirrhosis secondary to hepatitis B complicated by a small hepatocellular carcinoma [84],... 

Most patients with Wilson disease, whatever their clinical presentation, have some degree of liver disease. Chronic liver disease (if undiagnosed and untreated) may precede manifestation of neurological symptoms for more than 10 years. Patients can present with liver disease at any age. The most common age of hepatic manifestation is between 8 and 18 years, but cirrhosis may already be present in children below the age of 5. On the other hand, Wilson disease is diagnosed also in patients presenting with advanced chronic liver disease in their 50s or 60s, without neurological symptoms and without Kayser-Fleischer rings. 

A 70-year-old man with hypertension, congestive heart failure, atrial fibrillation, gastroesophageal refiux disease, chronic obstructive pulmonary disease, and chronic hepatitis C infection was stabilized on warfarin 36 mg/ week. He developed a hepatocellular carcinoma and started to take sorafenib 200 mg/ day. After 1 month his prothrombin time had risen to 85 s and his INR was 40. Sorafenib and warfarin were withdrawn, and after reintroduction of warfarin his INR stabilized on a dosage of 36 mg/week. Sorafenib 200 mg/ day was again introduced, and about 2 weeks later the INR rose to 4.7. Sorafenib was withdrawn permanently. 

Hematologic diseases autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, pernicous anemia Kidney disease Goodpasture syndrom, lipoid nephroses, minimal change glomerulonephritis Diseases of the gastrointestinal tract autoimmune chronic active hepatitis, autoimmune atrophic gastritis, Crohn s disease, ulcerative colitis... 

Disorders of lipoprotein metabolism involve perturbations which cause elevation of triglycerides and/or cholesterol, reduction of HDL-C, or alteration of properties of lipoproteins, such as their size or composition. These perturbations can be genetic (primary) or occur as a result of other diseases, conditions, or drugs (secondary). Some of the most important secondary disorders include hypothyroidism, diabetes mellitus, renal disease, and alcohol use. Hypothyroidism causes elevated LDL-C levels due primarily to downregulation of the LDL receptor. Insulin-resistance and type 2 diabetes mellitus result in impaired capacity to catabolize chylomicrons and VLDL, as well as excess hepatic triglyceride and VLDL production. Chronic kidney disease, including but not limited to end-stage... 

Hepatocellular carcinoma (HCC) develops in patients with chronic liver diseases associated with hepatitis B and hepatitis C vims infections with high incidences. Here, an acyclic retinoid has been shown to suppress the posttherapeutic recurrence after interferon-y or glycerrhicin treatment in cirrhotic patients who underwent curative treatment of preceding tumors. The retinoid induced the disappearance of serum lectin-reactive a-fetoprotein (AFP-L3), a tumor marker indicating the presence of unrecognizable tumors in the remnant liver, suggesting a deletion of such minute (pre)malignant clones (clonal deletion). As a molecular mechanism of the clonal deletion, a novel mechanism of... 

Carroll KM, Ball SA, Nich C, et al Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence. Arch Gen Psychiatry 38 755-761, 2001 Centers for Disease Control and Prevention Recommendation for prevention and control of hepatitis (virus (HCV) infection and HCV-related chronic disease. MMWR Recommendations and Reports 47(RR19) l-39, 1998 Charney DS, Steinberg DE, Kleber HD, et al The clinical use of clonidine in abrupt withdrawal from methadone. Arch Gen Psychiatry 38 1273-1277, 1981 Charney D S, Heninger OR, Kleber H D The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone. Am J Psychiatry 143 831-837, 1986... 

GaetaGB, Stroffolini T, Chiaramonte M, Asdone T, Stomaiuolo G, LobeUo S, Sagnelli E, Brunetto MR, Rizzetto M (2000) Chronic hepatitis D a vanishing disease An Italian multicenter study. Hepatology 32 824-827... 

A broad and vigorons T cell response generally accompanies elimination of HBV as well as HCV infection. By contrast, patients with chronic hepatitis B or C tend to have late, transient, or narrow T cell responses. In a long-term follow-up of HBV-infected patients receiving HPC transplants from HBV-immune individuals, 20 of 31 recipients cleared their HBV infection (Hui et al. 2005). In principle, these results encourage the development of adoptive T cell transfer strategies for the treatment of chronic viral hepatitis. However, it is still controversial whether induction of an efficient T cell response is the cause or the consequence of viral clearance. Furthermore, T cell responses do not only contribute to virus control but also to disease pathology (Rehermann and Nascimbeni 2005). 

Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351(15) 1521-1531 Lindahl K, Stable L, Bruchfeld A, Schvarcz R (2005) High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 41(2) 275-279... 

Cirrhosis is the result of long-term insult to the liver, so damage is typically not evident clinically until the fourth decade of life. Chronic liver disease and cirrhosis combined were the 12th leading cause of death in the United States in 2002. In patients between the ages of 25 and 64, damage from excessive alcohol use accounted for over one-half of the deaths.2 Alcoholic liver disease and viral hepatitis are the most common causes of cirrhosis in the United States and worldwide. 

---